Sitara Tx engineers neuroprotective astrocytes that halt neurodegeneration at its source — a disease-agnostic, mutation-agnostic platform applicable across ALS, Parkinson's disease, spinal cord injury, and beyond.
The Problem
Across neurodegenerative diseases — ALS, Parkinson's, spinal cord injury, and others — the field has focused on protecting or replacing neurons. But neurons are the casualties, not the cause.
Dysfunctional astrocytes are the orchestrators of neuronal demise. They release toxic factors, withdraw trophic support, and amplify neuroinflammation regardless of the underlying genetic mutation or disease etiology. No approved therapy addresses this shared driver.
The Biology
Astrocyte dysfunction is not specific to one disease or one mutation. It is a convergent mechanism across neurodegeneration: in ALS, Parkinson's, and spinal cord injury alike, reactive astrocytes actively destroy the neurons they are meant to protect. A therapy that restores astrocyte health addresses all of them.
Neuroprotective astrocytes clear excess glutamate from synaptic clefts, preventing excitotoxic neuronal death — a shared mechanism in ALS, Parkinson's, and spinal cord injury where this clearance is lost.
Healthy astrocytes maintain the barrier shielding neurons from circulating toxins and immune infiltration. BBB dysfunction is an early, disease-agnostic driver of neurodegeneration across CNS conditions.
Reactive astrocytes drive chronic neuroinflammation regardless of mutation or etiology. Neuroprotective astrocytes secrete anti-inflammatory factors (e.g. IL-4) that break this cycle across disease contexts.
Release of BDNF and GDNF sustains motor and dopaminergic neuron survival. This trophic support is withdrawn in ALS, Parkinson's, and SCI — and can be restored by transplanted therapeutic astrocytes.
Our Technology
Our DL4-bead platform produces astrocytes with a validated neuroprotective identity — low A1 neurotoxic score, moderate A2 neuroprotective score — regardless of the target disease or the patient's genetic background. Because astrocyte dysfunction is a convergent mechanism, one optimized cell product addresses many conditions. The platform produces therapeutic astrocytes in ~2 months, versus 4–6 months for competing approaches.
Profiled the developing human brain to map gene expression during native astrocyte formation.
Identified a critical Notch signaling spike before astrocyte fate commitment — the precise moment to intervene.
Engineered DL4-coated microbeads that deliver this exact Notch signal to neural progenitor cells at day 14–21 of differentiation.
DL4-astrocytes show low A1 neurotoxic scores and moderate A2 neuroprotective scores — confirmed by scRNA-seq, flow cytometry, and functional assays.
DL4-astrocytes score low as A1 neurotoxic and moderately as A2 neuroprotective — validated by single-cell transcriptomics against primary fetal astrocytes.
~2 months versus the 4–6 months of competing approaches — critical for rapidly progressing conditions like ALS and acute spinal cord injury where time to treatment is everything.
Off-the-shelf product from HLA-matched iPSC lines enables broad treatment access — with an autologous option to minimize immune rejection.
Platform architecture supports next-generation engineered astrocytes — correcting disease mutations or overexpressing protective factors like NRF2 and IL4.
International patent filed (WO2025231103, Arc Institute; inventors: Salvi & Konermann). Orphan Drug Designation eligible — 7-year US market exclusivity post-approval.
Programs
Because our neuroprotective astrocyte phenotype is disease-agnostic, the same DL4-bead manufacturing platform underpins programs across ALS, Parkinson's disease, and spinal cord injury — with engineered next-generation variants in parallel development.
| Program | Indication | Target | Stage | Status |
|---|---|---|---|---|
| SIT-1 Lead Program |
ALS | Allogeneic Astrocytes |
|
Active |
| SIT-2 ALS Engineering |
ALS | Engineered Astrocytes |
|
Active Investigation |
| SIT-3 | Spinal Cord Injury | Allogeneic Astrocytes |
|
Pending SIT-1 IND |
| SIT-4 | Parkinson's Disease | Engineered Astrocytes |
|
Pending SIT-1 IND |
The Team
Sitara Tx was founded from Stanford and Arc Institute — at the intersection of stem cell biology, gene editing, and translational neuroscience.
Development Roadmap
Two parallel tracks — cell therapy toward the clinic, and a drug screening platform generating near-term non-dilutive revenue and validation data.
Patient iPSC co-culture validation across ALS (SOD1, TDP-43), Parkinson's, and SCI models. Drug screening revenue from DL4-astrocyte platform partnerships comes online, providing non-dilutive capital and cross-disease validation data.
Safety pharmacology, biodistribution, and toxicology in lead indication rodent models. Preparation for Orphan Drug and Fast Track Designation filings with the FDA. Platform's mutation-agnostic efficacy documented across genetic subtypes.
Multi-line optimization, GMP process development, and cryopreservation validation for allogeneic manufacturing at clinical scale — one process, deployable across all pipeline indications.
First-in-human dose escalation in lead indication patients. Drug screening platform commercially active in parallel. Clinical signal in lead program de-risks and accelerates subsequent indications.
Get in Touch
We are actively seeking seed investment, pharma partnerships, and academic collaborations to advance our astrocyte platform toward the clinic.